Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 8 studies | 21% ± 7% | |
brain | 7 studies | 30% ± 15% | |
lung | 5 studies | 20% ± 5% | |
heart | 4 studies | 20% ± 2% | |
lymph node | 4 studies | 20% ± 4% | |
adipose | 4 studies | 35% ± 18% | |
kidney | 3 studies | 17% ± 2% | |
liver | 3 studies | 28% ± 12% | |
intestine | 3 studies | 23% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2464.83 | 1445 / 1445 | 100% | 12.58 | 183 / 183 |
intestine | 100% | 4322.96 | 966 / 966 | 100% | 13.66 | 526 / 527 |
prostate | 100% | 4437.56 | 245 / 245 | 100% | 14.94 | 501 / 502 |
ovary | 100% | 4141.02 | 180 / 180 | 100% | 13.73 | 429 / 430 |
thymus | 100% | 5783.95 | 653 / 653 | 100% | 17.50 | 603 / 605 |
lung | 100% | 3883.98 | 578 / 578 | 100% | 12.44 | 1151 / 1155 |
stomach | 100% | 2733.28 | 359 / 359 | 100% | 12.15 | 285 / 286 |
liver | 100% | 5136.84 | 226 / 226 | 100% | 12.44 | 404 / 406 |
pancreas | 100% | 2331.41 | 328 / 328 | 99% | 14.12 | 177 / 178 |
uterus | 100% | 4143.92 | 170 / 170 | 99% | 10.79 | 455 / 459 |
kidney | 100% | 3993.16 | 89 / 89 | 99% | 24.10 | 891 / 901 |
breast | 100% | 3769.26 | 459 / 459 | 99% | 11.55 | 1105 / 1118 |
bladder | 100% | 3065.14 | 21 / 21 | 99% | 10.92 | 498 / 504 |
adrenal gland | 100% | 2732.09 | 258 / 258 | 97% | 7.51 | 222 / 230 |
skin | 100% | 1861.08 | 1805 / 1809 | 95% | 8.96 | 447 / 472 |
brain | 92% | 1033.29 | 2440 / 2642 | 100% | 12.56 | 704 / 705 |
adipose | 100% | 4088.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 17.92 | 29 / 29 |
spleen | 100% | 6286.65 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2258.29 | 1332 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1969.21 | 800 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2060.77 | 852 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2998.11 | 918 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 9.31 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 90% | 7.43 | 72 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0016829 | Molecular function | lyase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0008483 | Molecular function | transaminase activity |
GO_0005515 | Molecular function | protein binding |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
Gene name | PHYKPL |
Protein name | 5-phosphohydroxy-L-lysine phospho-lyase 5-phosphohydroxy-L-lysine phospho-lyase (EC 4.2.3.134) (Alanine--glyoxylate aminotransferase 2-like 2) |
Synonyms | AGXT2L2 PP9286 |
Description | FUNCTION: Catalyzes the pyridoxal-phosphate-dependent breakdown of 5-phosphohydroxy-L-lysine, converting it to ammonia, inorganic phosphate and 2-aminoadipate semialdehyde. . |
Accessions | H7BXR0 H0YAK5 D6RD89 H0Y9N3 ENST00000476170.2 D6RAR0 ENST00000308158.10 [Q8IUZ5-1] ENST00000323594.8 H7BYK2 ENST00000393488.2 ENST00000493197.5 ENST00000474052.5 D6RCB8 ENST00000506045.1 ENST00000510913.5 Q8IUZ5 |